Method for myocardial revascularization in case of coronary artery disease
SUBSTANCE: combined effect on the myocardium is provided, including laser treatment and intramyocardial administration of autologous bone marrow stem cells (ABMSC). Through channels in the left ventricular wall in the myocardial ischemia area or areas are performed, with diameter of 0.3-1.0 mm and frequency of one channel per 1 cm2 of the left ventricle wall. Each channel is perpendicular to the left ventricle outer wall surface in the channel forming area. Channels are formed using the impact of CO2 laser, with a power of 800-1000 W and pulse duration of 20-50 ms. The pulse duration is chosen sufficient to form a channel by one pulse within the refractory period of the cardiac cycle. Then, 200 l of a solution containing 8.3 million of ABMSC is administered around each channel along its entire length using one injection. The needle is directed in the avascular zone at a distance of 1-2 mm from the outer channel wall. ABMSC is introduced when extracting the needle.
EFFECT: reduction of intervention trauma, while maintaining its efficiency, reducing the volume of fluid injected with ABMSC, as well as application of one pulse to form a through channel in the myocardium, prevention of intraoperative complications and induced arrhythmia due to the laser pulse impact by forming channels in the myocardium within the refractory period of the cardiac cycle.
SUBSTANCE: device for the endoluminal treatment of a blood vessel comprises a flexible wave guide with a light guide tube. The wave guide has an elongated axis, a proximal end with a connector for optical connection to a laser light source, a distal end placed in the blood vessel and comprising an emitting surface for the emission of light from the light source sideways in relation to the elongated axis of the wave guide onto a surrounding vascular wall segment extending within the angular range. The device is provided with a secondary laser light source, a reflected light reception detector, a laser light transparent cone-shaped primary diffuser (1) with laser light deflection and a secondary diffuser (3) extending the laser light coverage area. The primary diffuser (1) is mounted at an optical output of the wave guide between the emitting surface of the wave guide and a sapphire safety cap (2). The secondary diffuser (3) is mounted between the safety cap (2) and the primary diffuser (1). The device also comprises a detachable sterilised protective sheath (4). The protective sheath (4) is made from heat-shrinkage polytetrafluoroethylene, configured as a tube with an ultrasound contrast insert and mounted on the wave guide over the safety cap (2).
EFFECT: using the invention is expected to improve the quality of blood vessel coagulation, eliminating light guide burning and reducing its friction on the blood vessel.
2 cl, 3 dwg
SUBSTANCE: opening of a carious cavity, ablation of overhanging enamel edges on the entire circumference, necrectomy and drug treatment with a 0.06% chlorhexidine solution are performed. The preparation "Lemifaren" is applied on walls and bottom of the carious cavity in a uniform 1 mm thick layer, which is left for 1 day under temporary filling. After the removal of the preparation irradiation in a pulse mode with the power of 5 W and frequency of 2000-3000 Hz is carried out for 5 min with the application of the laser apparatus ALST-01. After that, the cavity is restored with an account of functional and aesthetic parameters of the particular tooth.
EFFECT: effective treatment of deep caries prevents caries recurrences and pulp inflammation.
SUBSTANCE: transurethral bladder resection enables the exposure of tumour bed tissues to pulse laser light of wave length 970 nm and emitting power from 10 to 15 Wt. The exposure involves contacting a light guide to bladder wall wound tissues until visualising the coagulation changed within the contact exposure. That is combined with advancing the light guide spirally from the wound periphery to the tumour bed centre. A method involves improving the therapeutic effect by preventing the tumour recurrences, preventing erythrocyturia and developing complications caused by intraoperative complications, as well as preventing complications caused by the deep thermal exposure on the bladder wall.
EFFECT: improving the oncologic surgical effect is ensured by eliminating the tumour cell migration along the tumour bed vessels by the primary coagulation of the peripheral sections of the treated bed.
3 cl, 3 ex
SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used in treating patients suffering from rheumatoid arthritis. The method involves prescribing methotrexat 15 mg a week per os, folic acid 5 mg a week per os, movalis 15 mg a day per os. If the patient has the second degree of activity of rheumatoid arthritis, IL-1β of 1.3±0.3 pg/ml and more, IL-6 of 1.5±0.3 pg/ml and more, TNF-α of 1.78±0.35 pg/ml and more, IL-4 of 3.7±0.34 pg/ml and less, leptine of 6.4±0.42 pg/ml and more, glycosaminoglycans of 0.310±0.032 g/l, 7 daily procedures of intravenous laser exposure are prescribed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes. If observing the third degree of activity, IL-1β of 2.01±0.18 pg/ml and more, IL-6 of 3.01±0.38 pg/ml and more, TNF-α of 3.3±0.25 pg/ml and more, IL-4 of 1.3±0.24 pg/ml and less, leptine of 8.8±0.72 pg/ml and more, glycosaminoglycans of 1.3±0.54 g/l, 10 daily procedures are performed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5-2.0 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes.
EFFECT: method enables reducing a rate of aggravations, an intensity of clinical manifestations, drug load on the patient, prolonging remissions ensured by a normalising effect on cytokine dynamics - reduced pro-inflammatory and increased anti-inflammatory cytokines.
SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.
EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.
SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and can be used in treating amblyopia in children. One 10-minute procedure involves alternating 1-2-minute exposure to green-range laser speckle structures at wavelength 0.5-0.65 mcm and red-range laser speckle structures at wavelength 0.63-0.7 mcm. Laser fluence is (4-8)×10-5 W/cm2. That is combined with autoscan exposure to a travelling magnetic field from temporal lobes to an occipital region by bitemporal method at a scan frequency of 90-180 Hz. A field density is 30-45 mT. The procedures are daily for 10 days.
EFFECT: method provides stimulating the maximum count of retinal cells responsible for colour vision, prevents the eye tissue adaptation to laser light, optimises delivering visual pulses along the visual pathway to the visual cortex.
1 tbl, 2 ex
SUBSTANCE: implementing the presented method involves mixing gel Hyaludent 1 ml on a slide with Betaleukin 0.0005 ml dissolved in water for injections 1 ml; the produced content is applied with a single application syringe on a desalivated treated area of the involved periodontal tissues and left until completely absorbed for 1-3 minutes; the involved area is exposed to laser light generated by the laser semiconductor dental therapeutic apparatus Optodan with a periodontal tip in the mode II, with the exposure length for 3-5 minutes; the therapeutic course is 8 days daily.
EFFECT: using the method enables achieving the fast regeneration length, ensuring the intact periodontal state in the most patients.
4 tbl, 3 ex
SUBSTANCE: method involves the fasting oral administration of placenta hydrolysate 2ml in water 200 ml at a temperature of 37°C in the morning. After that, the patient is laid down on his/her back and exposed to infrared laser light generated by the laser scanning physiotherapeutic simulator SLSF-03.2 IK. An initial end face output power is 2 mW at a power flow density of 50 mW/cm2 on a projection of an ulcer defect on frame No. 57 or No. 59 with laser light modulation at a frequency of 12-15 a second for 3 minutes per one field. That is followed by exposing a projection of a bend of the elbow on frame No. 30 or No. 40 for 10 minutes per a field. Further, the patient stays in the same position to perform transcranial electric stimulation generated by the Doctor TES-03 apparatus. A gel forehead electrode (+) is applied in the middle of the forehead skin until adhered to the skin uniformly. Two gel postaural electrodes are applied on bony mastoid processes (-) until adhered to the skin uniformly. The electrodes are fixed with a headband. The exposure has a current intensity of 1.5 mA in the form of a bipolar pulsing frequency of 77.5 Hz for 20 minutes. The therapeutic course makes 10 daily procedures.
EFFECT: method provides reducing pain and dyspeptic syndromes, asthenovegetative syndrome, accelerating ulcerous process healing in the mucous membrane, achieving a stable remission, normalising the functional state of the adjacent organs, namely the liver, pancreas, reducing a desire to smoke up to a complete smoking cessation completely for the whole period of treatment.
4 tbl, 2 ex
SUBSTANCE: first stage involves the antegrade palpation-assisted insertion of a heavy-ended phlebextractor through an incision at the medial malleolus to straighten varicose segments. The phlebextractor is removed thereafter from the incision at the medial malleolus. Tumescence anaesthesia is applied along the vein trunk. That is followed by the coagulation of an inconsistent tibial segment of the great saphenous vein with the use of a laser light guide. The laser light guide is removed from the incision at the medial malleolus. A cosmetic stitch is applied on the wound. At the second stage: the heavy-ended phlebextractor is inserted palpation-assisted in the retrograde direction through a cross-ectomy incision to straighten varicose segments. The heavy-ended phlebextractor is used to remove any inconsistent valves, and an aiming beam controlled laser light guide is delivered along the phlebextractor. Thereafter, the phlebextractor is taken out of the cross-ectomy incision. Tumescence anaesthesia is applied. That is followed by the laser coagulation of an inconsistent femoral segment of the vein. The laser light guide is taken out of the cross-ectomy incision. The great saphenous vein stump is ligatured. The wound is closed. The whole surgical procedure is continuously ultrasound-controlled.
EFFECT: method enables the laser light guide coagulation of the inconsistent segments of the vein causing no paravasal inflammatory reaction, delivering the laser light guide precisely by using the heavy-ended phlebextractor.
SUBSTANCE: as medications administered are: methotrexate 15 mg per week intake, folic acid 5 mg per week intake, movalis 15 mg per day intake. Laser therapy is administered in differential way depending on degree of disease activity and level of glucosaminoglycanes (GAG). In case of second stage of rheumatoid arthritis - index DAS28 3.2-5.1, level of glucosaminoglycanes 0.510±0.032 g/l, 7 daily procedures of intravenous laser irradiation are carried out. Radiating head KL-VLOK with wavelength 635 nm, power at the end of disposable light guide 1.5 mW, exposure time 15 minutes and laser head KL-VLOK-365 with wavelength 365 nm, power at the end of light guide 1.0 mW, exposure time 5 minutes, are alternated. In case of third degree of activity index DAS28 is higher than 5.1, GAG level is equal or is higher than 0.618±0.069 g/l, 10 procedures are carried out Radiating head KL-VLOK with wavelength 635 nm, power at outlet of disposable light guide 1.5-2.0 mW, exposure time 15 minutes and laser head KL-VLOK-365 nm, power at outlet of disposable light guide 1.0 mW, time of exposure 5 minutes.
EFFECT: method makes it possible to reduce frequency of exacerbations, reduce expression of clinical manifestations, reduce drug load on patient, provides earlier arrest of disease symptoms due to differentiated approach in case of administration of intravenous laser irradiation of blood and its normalising action on GAG indices and reduction of disease activity degree.
FIELD: veterinary medicine.
SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.
EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.
2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new (R)-stereoisomers of substituted 2-thioxo-imidazolidin-4-ones of formula 1 or to spiroanalogues thereof, which possess the properties of an androgen receptor agonist, to versions of a method for producing them, and to intermediate compounds 2.1-2.4 for producing compounds of formula 1. The invention also refers to a pharmaceutical composition presented in the form of tablets, capsules, injections. In formula 1 R1 represents OH, NH2, or OR4 group; R2 and R3 represent methyl, or R2 and R3 represent CH2-CH2 group; R4 represent C1-C4alkyl or cyclopropyl. The compounds 2.1-2.4 are described by structural formulas:
EFFECT: compounds of formula 1 can be used for producing the medicinal product applicable for treating a cancer disease, such as prostate cancer, breast cancer.
17 cl, 1 tbl, 10 ex
SUBSTANCE: group of inventions relates to medicine, namely to a method of treatment or prevention of epilepsy. For this purpose recombinant human interleukin-2 is introduced to the patient with a reduced BDNF concentration in blood serum and/or plasma. The group of inventions also relates to the application of interleukin-2 for the treatment or prevention of the said disease.
EFFECT: application of the claimed group of inventions makes it possible to apply recombinant interleukin-2 as a single therapeutic agent in the treatment of pharmacoresistant epilepsy, associated with the insufficient BDNF production.
8 cl, 5 tbl, 3 ex
SUBSTANCE: what is presented is using meso-tetra(3-pyridyl)bacteriochlorin of structural formula (I) as a near-infrared photosensitiser for a photodynamic therapy. Doses 1.0-2.5 mg/kg of the declared photosensitiser have provided 70-100% tumour growth inhibition, 80-131% increase in life expectancy and 25-100% animals' recovery by selective tumour collection and fast clearance.
EFFECT: high photoinduced activity on human tumour cells of various epithelial origin and high dose-dependent anti-tumour effectiveness in the animal with tumours of various origins.
5 dwg, 8 ex
SUBSTANCE: cryoprotector is opened in a laminar flow unit; a special syringe of asyringe pump is filled with a cryoprotector; that is followed by introducing a filter solution of the cryoprotector - 55% dimethylsulphoxide with 5% dextran 40 at temperature +4°C in a nucleated cell suspension with haemopoietic stem cells in a cryopackage with the concentrate and mixing mechanically in a mixing apparatus, transferring the system together with the cryoprotector flask into the laminar flow unit; the air is released from the cryopackage and portion of the suspension; the package is sealed and placed into a shrink bag; that is followed by programmed multi-stage freezing, the first stage of which keeping the mixture of the suspension with the stem cells and cryoprotector - a freezing sample - for 10 min at temperature +4°C; the second stage is cooled at a rate of 1°C/min to temperature -12°C; the thirst stage provides cooling at a rate of 20°C/min to temperature -60°C; at the fourth stage, the sample is heated at a rate of 10°C/min to temperature -18°C; at the fifth stage, the sample is cooled at a rate of 1°C/min to -60°C; at the end of the freezing program, the sample is cooled at a rate of 3°C/min to temperature -100°C; after freezing, the sample is placed into a quarantine dewar with liquid nitrogen until infection and bacteriological fungal contamination test results are obtained. After termination of the quarantine shelf life, the sample with haemopoietic stem cells are placed for long-term storage at temperature not exceeding -150°C, into the dewar with liquid nitrogen if observing negative test results. If the infection and bacterial and/or fungal contamination test results are positive, the sample with haemopoietic stem cells are transferred into the dewar with liquid nitrogen for infectious material for long-term storage.
EFFECT: invention enables increasing cell viability in the sample.
3 cl, 4 dwg
SUBSTANCE: invention refers to medicine, particularly to oncourology, and can be used in the non-surgical treatment of the patients suffering early stages of prostate malignant tumour. A method of treating prostate cancer with using prolonged prodrug of octreotide accompanying surgical or drug-induced castration involves a) measuring pre-therapeutic prostate-specific antigen; b) measuring pre-therapeutic blood plasma chromogranin A; c) selecting the patients having high blood chromogranin A of more than 3 nmol/l; d) conducting a therapy with prolonged prodrug of octreotide in a combination with dexamethasone in the selected patients; e) controlling the prostate-specific antigen variation every month and monitoring a decrease thereof in the patients by measuring it intra-therapeutically according to the stage d); the therapeutic efficacy according to the stage d) is evaluated by a therapeutic response, which is accompanied by maximum decrease of the prostate-specific antigen.
EFFECT: invention enables providing the higher therapeutic efficacy in the patients suffering prostate cancer at the different stages.
3 cl, 1 tbl, 5 ex
SUBSTANCE: invention refers to medicine, namely to balneology. A balneological agent for treating and preventing various diseases is prepared by the gradual and sequential mixing at room temperature of yellow clay, natural brine of Bolshoy Tambukan Lake, sage essence, dimethyl sulphoxide in certain relations.
EFFECT: agent possesses the more prominent therapeutic effect.
5 tbl, 2 ex
SUBSTANCE: tissue-specific matrix is obtained by performing a perfusion washing and a decellularisation of a parenchymal organ. Herewith 60-120 minutes before the perfusion washing of the donor organ, measures to prevent intravascular blood cell aggregation and microcirculation disturbances are taken and involve the intramuscular or intravenous administration of a disaggregant or disaggregants (heparin and trental) into a donor. That is followed by an organ perfusion by administering into its vascular bed phosphate-buffered normal saline of the following composition: 138 mM NaCl, 2.67 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, distilled water up to 1l and containing 1% serum albumin and 10-15% glycerol or 10-15% dimethyl sulphoxide with pH 7.4 in an amount equal to a double amount of the vascular bed of the organ at a perfusion pressure of 100-120 mm Hg in its arterial system. Thereafter, the decellularised organ is ground to a particle size of 0.5mm to 4mm; the ground fragments are portioned in an amount of 5-10g, and each portion is frozen by immersing into liquid nitrogen gas for 5-10 minutes. The frozen portions are re-ground to a particle size of no more than 600 mcm; then each portion is de-frozen by re-suspending in phosphate-buffered normal saline 30-70ml of the following composition containing 138 mM NaCl, 2.67 mM KCl, 1.47 mM KH2PO4, 8.1 mM Na2HPO4, distilled water up to 1l , with pH 7.4, at a room temperature. The prepared suspension is cleaned from the particles of less than 200mcm; the prepared fraction is lyophilised and sterilised to prepare the target matrix samples.
EFFECT: using the invention enables providing the more complete decellularisation procedure ensured by preventing the disturbed microcirculation in the donor organ, providing higher density and uniformity of the re-cellularisation of the entire matrix and easier control thereof by increasing the matrix adhesive surface areas for the contact to inoculating cells as prepared in the form of powder.
4 cl, 5 ex, 9 dwg
SUBSTANCE: invention relates to new heterogeneous ring compounds containing a pentatomic rings, condensed with other nuclei, only with one atom of oxygen as a heteroatom, namely to derivants of acetamid N-((1S)-1',2',3'-trimethoxy-6,7-dihydro-1H-benzo[5',6':5,4]cyclohepta-[3,2-f]benzofuran-1-il) with the general formula 1 , where R - substituent, R=Ph, pyridine-2-il, CH2OH, CH(CH3)OH, CH2CH2OH, CH2OAc, (CH2)8CO2Me or CH2N(CH2CH3)2, and also to their application as an active component of antitumoral medicinal preparation.
EFFECT: increase of activity with inhibition of proliferation of the tumour cells.
10 cl, 3 dwg, 8 ex
SUBSTANCE: set task is solved by application of final slag, formed in production of ferrovanadium by alumino-silicothermic method as bactericidal material.
EFFECT: extension of raw material resources for bactericidal materials.
FIELD: pharmaceutical industry and technology, pharmacy.
SUBSTANCE: invention relates to a method for preparing extract based on walnuts at milkwax stage of ripeness. Method for preparing extract based on walnuts involves grinding walnuts at milkwax stage of ripeness taken with pericarps, drying to air-dry state, mixing with wild rose fruits ground and dried to air-dry state and taken in the definite ratio of components followed by treatment with aviation kerosene and stirring at room temperature. Method provides preparing extract with the higher content of biologically valuable substances and to increase the assortment of vegetable supplements.
EFFECT: improved preparing method.